BioCentury | Apr 12, 2017
Clinical News

Trerief: Ph III data

...patients with Parkinsonism accompanying dementia with Lewy bodies showed that once-daily 25 and 50 mg Trerief...
...Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Zonegran zonisamide ( Trerief , Excegran) ( E2090 , AD-810N...
...UPDRS) Part III total score at week 12 Status: Phase III data Milestone: NA Jaime De Leon AD-810N E2090 Excegran Trerief Zonegran zonisamide Sumitomo...
BioCentury | Dec 15, 2014
Clinical News

Zonegran zonisamide regulatory update

...Russia approved Zonegran zonisamide from Eisai to treat partial epilepsy in children and adolescents. The anticonvulsant...
...newly diagnosed epilepsy and as adjunctive therapy in patients ages =6 years. Sumitomo Dainippon markets zonisamide...
...Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Zonegran zonisamide ( Excegran ) ( E2090 , AD-810N...
BioCentury | Sep 22, 2014
Strategy

Weighing in on obesity

...lemon balm) ethyl acetate dried extract Ph III (complete 2015) Orexigen Therapeutics Inc. (NASDAQ:OREX) Empatic zonisamide...
...bupropion SR Fixed dose combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, and anticonvulsant zonisamide...
BioCentury | Sep 15, 2014
Company News

Eisai, Concordia deal

...Eisai will sell to Concordia U.S. and Puerto Rican commercialization rights to anticonvulsant Zonegran zonisamide. Eisai...
...will be Concordia's supplier of the product that blocks sodium (Na) and calcium (Ca) channels. Zonegran...
...Co. plc (NYSE:PRGO; Tel Aviv:PRGO, Dublin, Ireland) acquired, divested North American and European rights to Zonegran...
BioCentury | May 5, 2014
Company News

Eisai sales and marketing update

...Eisai launched Zonegran zonisamide in Russia to treat partial seizures, with or without secondary generalization, in...
...to treat partial seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy. Zonegran...
BioCentury | Mar 17, 2014
Clinical News

Zonegran zonisamide regulatory update

...The Scottish Medicines Consortium (SMC) recommended the restricted use of Zonegran zonisamide from Eisai on the...
...sodium (Na) and calcium (Ca) channels from Dainippon, which markets zonisamide as Excegran in Japan. Zonisamide...
...Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Zonegran zonisamide ( Excegran ) ( E2090 , AD-810N...
BioCentury | Jan 27, 2014
Clinical News

Zonegran zonisamide regulatory update

...Eisai said Swissmedic approved a label expansion for Zonegran zonisamide to include use as adjunctive therapy...
...sodium (Na) and calcium (Ca) channels from Dainippon, which markets zonisamide as Excegran in Japan. Zonisamide...
...Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Zonegran zonisamide ( Excegran ) ( AD-810N , E2090...
BioCentury | Dec 16, 2013
Company News

Esteve, Eisai sales and marketing update

...Eisai partnered with Esteve to promote epilepsy drug Zonegran zonisamide in Spain. Zonegran is approved to...
BioCentury | Nov 18, 2013
Clinical News

Trerief zonisamide: Phase II started

...placebo-controlled, Japanese Phase II trial to evaluate oral Trerief in about 150 patients. Eisai markets zonisamide...
...American and European rights to zonisamide from Dainippon, which markets zonisamide as Excegran in Japan. Zonisamide...
...Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Trerief zonisamide ( Zonegran ) ( AD-810N , E2090...
BioCentury | Oct 28, 2013
Clinical News

Zonegran zonisamide regulatory update

...Eisai said the Italian Medicines Agency (AIFA) granted Class A reimbursement for Zonegran zonisamide as monotherapy...
...sodium (Na) and calcium (Ca) channels from Dainippon, which markets zonisamide as Excegran in Japan. Zonisamide...
...Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Product: Zonegran zonisamide ( Excegran ) ( AD-810N , E2090...
Items per page:
1 - 10 of 115